长沙低价收U|【唯一TG:@heimifeng8】|Telegram账号盗取破解技术✨谷歌搜索留痕排名,史上最强SEO技术,20年谷歌SEO经验大佬✨JAMA: Popular weight loss drugs increase risk of vision loss
American scientists from Johns Hopkins University have found that the popular weight loss and diabetes drug semaglutide (part of the drugs Ozempic and Vegovy) may be associated with an increased chance of developing a rare eye disease - nonarteritic anterior ischemic optic neuropathy (NAION). This condition is capable of causing sudden vision loss. The study is published in the scientific journal JAMA Ophthalmology.
The team analyzed data from more than 37 million patients with type 2 diabetes, of whom more than 810 thousand were taking semaglutide. The results showed that users of the drug had a 32% higher risk of NAION compared to those who avoided semaglutide.
The researchers emphasized that the absolute risk remains low, and the link between semaglutide and NAION requires further study.
“We encourage clinicians to weigh the potential risk of this rare but serious eye disease against the numerous therapeutic benefits of semaglutide,” said study leader Dr. Cindy Cai.
Experts note that semaglutide has significant benefits, including blood sugar control, weight loss and reduced risk of cardiovascular disease.